Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance

Autor: Ketan Kavia, Tina Vilsbøll, Amar Ali, Ben D Prohaska, Juan J Gorgojo Martínez, Irene Hramiak, Akshay Jain, Sten Madsbad, Jodi L Strong, Louis Potier

Publikováno v: International Journal of Clinical Practice
Jain, A B, Ali, A, Gorgojo Martínez, J J, Hramiak, I, Kavia, K, Madsbad, S, Potier, L, Prohaska, B D, Strong, J L & Vilsbøll, T 2021, ' Switching between GLP-1 receptor agonists in clinical practice : Expert consensus and practical guidance ', International Journal of Clinical Practice, vol. 75, no. 2, e13731 . https://doi.org/10.1111/ijcp.13731

Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are an established treatment for patients with type 2 diabetes (T2D). Differences between GLP‐1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovasc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1de64fa58e45e1630eaf9b5ea69248ac
https://pubmed.ncbi.nlm.nih.gov/32975890